Review: taking Pepcid and Zantac together


Summary

Drug interactions are reported among people who take Pepcid and Zantac together. This review analyzes the effectiveness and drug interactions between Pepcid and Zantac. It is created by eHealthMe based on reports of 1,314 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Pepcid and Zantac >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Pepcid

Pepcid has active ingredients of famotidine. It is often used in gastrooesophageal reflux disease. (latest outcomes from Pepcid 23,084 users)

Zantac

Zantac has active ingredients of ranitidine hydrochloride. It is often used in indigestion. (latest outcomes from Zantac 35,120 users)

On Jul, 22, 2016

1,314 people who take Pepcid, Zantac are studied.


Number of reports submitted per year:

Pepcid and Zantac drug interactions.

Drug effectiveness over time:

Pepcid:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Zantac:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Pepcid:
  • female: 0.0% - (0 of 2 people)
  • male: 0.0% - (0 of 0 people)
Zantac:
  • female: 0.0% - (0 of 2 people)
  • male: 0.0% - (0 of 1 people)

Drug effectiveness by age:

Pepcid:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Zantac:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 2 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • dehydration
  • hypotension
  • sepsis
  • bk virus infection
  • cystitis haemorrhagic
  • cytomegalovirus infection
  • drug ineffective
  • hyperbilirubinaemia
  • mucosal inflammation
  • atrioventricular block complete
1 - 6 months:
  • anaemia
  • cerebral haemorrhage
  • enterocolitis
  • hepatic function abnormal
  • renal failure acute
  • respiratory failure
  • blood lactic acid increased
  • cholecystitis acute
  • haemoglobin decreased
  • iron deficiency
6 - 12 months:
  • aspartate aminotransferase increased
  • gamma-glutamyltransferase increased
  • alanine aminotransferase increased
  • blood alkaline phosphatase increased
  • blood lactate dehydrogenase increased
  • cardiac failure
  • cardio-respiratory arrest
  • depressed level of consciousness
  • dyspnoea
  • general physical health deterioration
1 - 2 years:
  • leukopenia
  • abdominal pain
  • anhedonia
  • anxiety
  • cholecystitis chronic
  • gallbladder disorder
  • haemolytic anaemia
  • heart rate irregular
  • hydronephrosis
  • lymphocele
2 - 5 years:
  • depression
  • osteoporosis
  • pyrexia
  • ankle fracture
  • arthritis
  • calcium deficiency
  • chills
  • dyspepsia
  • dysphagia
  • gastric disorder
5 - 10 years:
  • bronchitis
  • chest pain
  • chronic obstructive pulmonary disease
  • collapse of lung
  • confusional state
  • weight gain
  • weight loss
  • acute respiratory failure
  • altered state of consciousness
  • atelectasis
10+ years:
  • abdominal abscess
  • aneurysm ruptured
  • bronchial haemorrhage
  • sepsis
  • splenic haemorrhage
not specified:
  • pain
  • nausea
  • anxiety
  • fatigue
  • dyspnoea
  • vomiting
  • anaemia
  • depression
  • weight decreased
  • pyrexia

Most common drug interactions by gender *:

female:
  • nausea
  • pain
  • vomiting
  • depression
  • back pain
  • weight decreased
  • anxiety
  • oedema peripheral
  • diarrhoea
  • arthralgia
male:
  • pain
  • anxiety
  • nausea
  • pyrexia
  • fatigue
  • dyspnoea
  • injury
  • constipation
  • anaemia
  • cardiac failure congestive

Most common drug interactions by age *:

0-1:
  • pyrexia
  • abdominal distension
  • alopecia
  • blister
  • candidiasis
  • cyanosis
  • failure to thrive
  • fluid overload
  • gastroenteritis
  • hypertension
2-9:
  • death
  • apnoea
  • irritability
  • oesophagitis
  • overdose
  • vomiting projectile
10-19:
  • electrocardiogram qt prolonged
  • haemolytic anaemia
  • pain
  • abdominal pain
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • blood bilirubin increased
  • pyrexia
  • aggression
  • agitation
20-29:
  • pain
  • anxiety
  • vomiting
  • cholecystitis chronic
  • nausea
  • diarrhoea
  • jaundice
  • injury
  • headache
  • lymphadenopathy
30-39:
  • convulsion
  • pain
  • osteopenia
  • depression
  • insomnia
  • asthenia
  • weight decreased
  • anaemia
  • anxiety
  • nausea
40-49:
  • arthralgia
  • nausea
  • type 2 diabetes mellitus
  • chest pain
  • fatigue
  • pain
  • vomiting
  • dyspnoea
  • hypotension
  • depression
50-59:
  • depression
  • pain
  • dyspnoea
  • nausea
  • osteonecrosis of jaw
  • back pain
  • arthralgia
  • fatigue
  • anxiety
  • injury
60+:
  • pain
  • anxiety
  • nausea
  • bone disorder
  • pyrexia
  • weight decreased
  • anaemia
  • renal failure acute
  • dyspnoea
  • diarrhoea

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Pepcid and Zantac?

Can you answer these questions?

More questions for: Pepcid, Zantac

You may be interested in these reviews

More reviews for: Pepcid, Zantac

On eHealthMe, Pepcid (famotidine) is often used to treat gastrooesophageal reflux disease. Zantac (ranitidine hydrochloride) is often used to treat indigestion. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.